Publications
2024
- Vaccination contre la COVID-19 : recommandations pour le printemps 2024
- Programme de surveillance du pneumocoque : rapport 2021-2022
- Vaccination contre le méningocoque de sérogroupe Y au Québec dans un contexte d’incidence accrue des infections invasives
- Maladies évitables par la vaccination à déclaration obligatoire au Québec : rapport de surveillance 2022
2023
- Simplification du calendrier de vaccination contre la COVID-19 pour les personnes non vaccinées
- Avis concernant l’utilisation de nouveaux vaccins conjugués contre le pneumocoque
- Administration de doses de rappel du vaccin contre la COVID-19 : recommandations pour l’automne 2023
- Utilisation des vaccins à haute dose ou adjuvantés dans le Programme d’immunisation contre l’influenza
- Utilisation des vaccins bivalents à ARN messager pour la primovaccination
- Maladies évitables par la vaccination à déclaration obligatoire au Québec : rapport de surveillance 2019-2021
- Avis concernant l’utilisation de nouveaux vaccins conjugués contre le pneumocoque
Publications
2024
- Antenatal tetanus, diphtheria, and acellular pertussis (Tdap) immunization and risk of serogroup 19 IPD in children: An indirect cohort study
- Vaccination during pregnancy and modulation of IgG response to pertussis vaccines in infants: The impact of different vaccine formulations
- The safety of seasonal influenza vaccination among adults prescribed immune checkpoint inhibitors: A self-controlled case series study using administrative data
2023
- Neighborhood-level vaccine impact on COVID-19 infection and hospital admission in Quebec, Canada, during the Delta and early Omicron periods
- Antimicrobial susceptibilities of Neisseria gonorrhoeae in Canada, 2021
- Increase of invasive pneumococcal disease in children temporally associated with RSV outbreak in Quebec: a time-series analysis
- Burden of disease of respiratory syncytial virus in infants, young children and pregnant women and people
2022
- Summary of the National Advisory Committee on Immunization (NACI) Rapid Response: Updated interim guidance on Imvamune in the context of ongoing monkeypox outbreaks
- Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada
- Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study
- Do intentions lead to action? Results of a longitudinal study assessing determinants of Tdap vaccine uptake during pregnancy in Quebec, Canada
- Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada
- Séroprévalence du SRAS-CoV-2 chez les travailleurs de la santé de 10 hôpitaux du Québec, au Canada: étude transversale
- Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses